ImmunoGen Stock Forecast, Price & News

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

Is ImmunoGen a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock.
View analyst ratings for ImmunoGen or view top-rated stocks.

How has ImmunoGen's stock been impacted by Coronavirus?

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMGN stock has increased by 96.4% and is now trading at $6.62.
View which stocks have been most impacted by COVID-19.

Are investors shorting ImmunoGen?

ImmunoGen saw a decline in short interest in November. As of November 15th, there was short interest totaling 10,430,000 shares, a decline of 35.6% from the October 31st total of 16,200,000 shares. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is presently 6.7 days. Currently, 5.6% of the shares of the company are short sold.
View ImmunoGen's Short Interest.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for ImmunoGen.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings results on Friday, October, 29th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $9.20 million during the quarter, compared to the consensus estimate of $19.03 million. ImmunoGen had a negative net margin of 55.41% and a negative trailing twelve-month return on equity of 85.94%. The firm's revenue was down 49.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) earnings per share.
View ImmunoGen's earnings history.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen issued an update on its FY 2021 earnings guidance on Friday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65 million-$75 million, compared to the consensus revenue estimate of $70.61 million.

What price target have analysts set for IMGN?

6 brokerages have issued 1-year target prices for ImmunoGen's stock. Their forecasts range from $5.00 to $12.00. On average, they anticipate ImmunoGen's stock price to reach $8.90 in the next year. This suggests a possible upside of 34.4% from the stock's current price.
View analysts' price targets for ImmunoGen or view top-rated stocks among Wall Street analysts.

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:

• Mark Joseph Enyedy, President, Chief Executive Officer & Director
• Susan Altschuller, Chief Financial Officer & Senior Vice President
• Anna Berkenblit, Chief Medical Officer & Senior Vice President
• Thomas Ryll, Senior Vice President-Technical Operations
• Stacy A. Coen, Chief Business Officer & Senior Vice President

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.

Who are some of ImmunoGen's key competitors?

Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Repligen (RGEN), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of IMGN's competitors.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.59%), Wellington Management Group LLP (6.94%), Morgan Stanley (1.86%), Geode Capital Management LLC (1.69%), Lombard Odier Asset Management Switzerland SA (1.49%) and Candriam Luxembourg S.C.A. (1.26%). Company insiders that own ImmunoGen stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends for ImmunoGen.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Healthcare of Ontario Pension Plan Trust Fund, Two Sigma Advisers LP, Two Sigma Investments LP, Wellington Management Group LLP, Morgan Stanley, Dimensional Fund Advisors LP, and Citigroup Inc..
View insider buying and selling activity for ImmunoGen or view top insider-selling stocks.

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Granahan Investment Management Inc. MA, Pura Vida Investments LLC, Lombard Odier Asset Management Switzerland SA, Integral Health Asset Management LLC, M&G Investment Management Ltd., Creative Planning, and AXA S.A..
View insider buying and selling activity for ImmunoGen or or view top insider-buying stocks.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $6.62.

How much money does ImmunoGen make?

ImmunoGen has a market capitalization of $1.34 billion and generates $132.30 million in revenue each year. The biotechnology company earns $-44.37 million in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does ImmunoGen have?

ImmunoGen employs 79 workers across the globe.

Does ImmunoGen have any subsidiaries?

The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

When was ImmunoGen founded?

ImmunoGen was founded in 1981.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

Where are ImmunoGen's headquarters?

ImmunoGen is headquartered at 830 WINTER ST, WALTHAM MA, 02451.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at (781) 895-0600, via email at [email protected], or via fax at 781-895-0611.